Selected research
Industry Research
Peptide-based Drug Industry Research Report 2026
Market perspective
The global Peptide-based Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Peptide-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Peptide-based Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Peptide-based Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Peptide-based Drug include Takeda, Teva, Sanofi, J & J, Novartis, Merck, Eli Lilly, AbbVie and AstraZeneca, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Peptide-based Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Peptide-based Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide-based Drug Market by Company
Takeda
Teva
Sanofi
J & J
Novartis
Merck
Eli Lilly
AbbVie
AstraZeneca
The Medicines
Novo Nordisk
Ipsen
Ferring
Peptide-based Drug Segment by Type
Injection
Oral
Other
Peptide-based Drug Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
Peptide-based Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Peptide-based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
- Other
Applications
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
Companies covered
- Takeda
- Teva
- Sanofi
- J & J
- Novartis
- Merck
- Eli Lilly
- AbbVie
- AstraZeneca
- The Medicines
- Novo Nordisk
- Ipsen
- Ferring
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Peptide-based Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Injection
- 2.2.3 Oral
- 2.2.4 Other
- 2.3 Peptide-based Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Metabolic Disorders
- 2.3.4 Central Nervous System
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Peptide-based Drug Breakdown Data by Type
- 3.1 Global Peptide-based Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Peptide-based Drug Forecasted Market Size by Type (2027-2032)
4 Peptide-based Drug Breakdown Data by Application
- 4.1 Global Peptide-based Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Peptide-based Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Peptide-based Drug Market Perspective (2021-2032)
- 5.2 Global Peptide-based Drug Growth Trends by Region
- 5.2.1 Global Peptide-based Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Peptide-based Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Peptide-based Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Peptide-based Drug Market Dynamics
- 5.3.1 Peptide-based Drug Industry Trends
- 5.3.2 Peptide-based Drug Market Drivers
- 5.3.3 Peptide-based Drug Market Challenges
- 5.3.4 Peptide-based Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Peptide-based Drug Players by Revenue
- 6.1.1 Global Top Peptide-based Drug Players by Revenue (2021-2026)
- 6.1.2 Global Peptide-based Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Peptide-based Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Peptide-based Drug Head Office and Area Served
- 6.4 Global Peptide-based Drug Players, Product Type & Application
- 6.5 Global Peptide-based Drug Manufacturers Established Date
- 6.6 Global Peptide-based Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Peptide-based Drug Market Size (2021-2032)
- 7.2 North America Peptide-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Peptide-based Drug Market Size by Country (2021-2026)
- 7.4 North America Peptide-based Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Peptide-based Drug Market Size (2021-2032)
- 8.2 Europe Peptide-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Peptide-based Drug Market Size by Country (2021-2026)
- 8.4 Europe Peptide-based Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide-based Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Peptide-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Peptide-based Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Peptide-based Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Peptide-based Drug Market Size (2021-2032)
- 10.2 South America Peptide-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Peptide-based Drug Market Size by Country (2021-2026)
- 10.4 South America Peptide-based Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide-based Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Peptide-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Peptide-based Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Peptide-based Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Peptide-based Drug Business (2021-2026)
- 12.1.4 Takeda Peptide-based Drug Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Peptide-based Drug Business (2021-2026)
- 12.2.4 Teva Peptide-based Drug Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Peptide-based Drug Business (2021-2026)
- 12.3.4 Sanofi Peptide-based Drug Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 J & J
- 12.4.1 J & J Company Information
- 12.4.2 J & J Business Overview
- 12.4.3 J & J Revenue in Peptide-based Drug Business (2021-2026)
- 12.4.4 J & J Peptide-based Drug Product Portfolio
- 12.4.5 J & J Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Peptide-based Drug Business (2021-2026)
- 12.5.4 Novartis Peptide-based Drug Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Peptide-based Drug Business (2021-2026)
- 12.6.4 Merck Peptide-based Drug Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 Eli Lilly
- 12.7.1 Eli Lilly Company Information
- 12.7.2 Eli Lilly Business Overview
- 12.7.3 Eli Lilly Revenue in Peptide-based Drug Business (2021-2026)
- 12.7.4 Eli Lilly Peptide-based Drug Product Portfolio
- 12.7.5 Eli Lilly Recent Developments
- 12.8 AbbVie
- 12.8.1 AbbVie Company Information
- 12.8.2 AbbVie Business Overview
- 12.8.3 AbbVie Revenue in Peptide-based Drug Business (2021-2026)
- 12.8.4 AbbVie Peptide-based Drug Product Portfolio
- 12.8.5 AbbVie Recent Developments
- 12.9 AstraZeneca
- 12.9.1 AstraZeneca Company Information
- 12.9.2 AstraZeneca Business Overview
- 12.9.3 AstraZeneca Revenue in Peptide-based Drug Business (2021-2026)
- 12.9.4 AstraZeneca Peptide-based Drug Product Portfolio
- 12.9.5 AstraZeneca Recent Developments
- 12.10 The Medicines
- 12.10.1 The Medicines Company Information
- 12.10.2 The Medicines Business Overview
- 12.10.3 The Medicines Revenue in Peptide-based Drug Business (2021-2026)
- 12.10.4 The Medicines Peptide-based Drug Product Portfolio
- 12.10.5 The Medicines Recent Developments
- 12.11 Novo Nordisk
- 12.11.1 Novo Nordisk Company Information
- 12.11.2 Novo Nordisk Business Overview
- 12.11.3 Novo Nordisk Revenue in Peptide-based Drug Business (2021-2026)
- 12.11.4 Novo Nordisk Peptide-based Drug Product Portfolio
- 12.11.5 Novo Nordisk Recent Developments
- 12.12 Ipsen
- 12.12.1 Ipsen Company Information
- 12.12.2 Ipsen Business Overview
- 12.12.3 Ipsen Revenue in Peptide-based Drug Business (2021-2026)
- 12.12.4 Ipsen Peptide-based Drug Product Portfolio
- 12.12.5 Ipsen Recent Developments
- 12.13 Ferring
- 12.13.1 Ferring Company Information
- 12.13.2 Ferring Business Overview
- 12.13.3 Ferring Revenue in Peptide-based Drug Business (2021-2026)
- 12.13.4 Ferring Peptide-based Drug Product Portfolio
- 12.13.5 Ferring Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst